Support for LIfT Biosciences to Develop the LIFT Approach to a Universal Cancer Therapy

It is good to see that more of the promising technical approaches to aspects of aging, originally put forward by people in the SENS rejuvenation research network some years ago, are now making solid progress towards commercial implementation. The LIFT, or GIFT, approach to cancer therapy involves the transplantation of suitably aggressive leukocyte or granulocyte immune cells from a donor. At the time it was first demonstrated to be highly effective in mice, more than a decade ago, the underlying mechanisms were not well explored, and that always makes it hard to obtain further support from scientific funding institutions. This is despite the point that the approach has the potential to be a near universal cancer therapy, applicable to most or all forms of cancer, even at very late stages.

Thus, unfortunately, the work progressed only very slowly for some years, materially supported by philanthropic funding and non-profit efforts. This is not an unusual story when it comes to development of new medical biotechnologies. Our communities and institutions are not good at identifying the best of work taking place in the lab and organizing to push it forward towards the clinic in a timely manner. Fortunately it is now becoming much easier to raise venture capital for the development of ambitious new biotechnologies, and so the approach is under development by LIfT Biosciences, who just received an influx of funding from Kizoo Technology Ventures, a group well known for their support of SENS style rejuvenation therapies.

Kizoo, part of the Forever Healthy Foundation, has announced today that it will be supporting biotech company LIfT Biosciences, a company that focuses on creating a new generation of cancer therapies that use our own immune systems. LIfT Biosciences is developing a new type of cancer immunotherapy approach that uses neutrophils to seek and destroy all types of solid tumors. Neutrophils are a particular type of white blood cell that protect us from infections and perform other functions. They comprise around 40 to 60 percent of the total number of white blood cells in our bodies and are the first immune cells to arrive during a bacterial infection.

The company is developing the world's first cell bank of neutrophils that are designed to seek and destroy any solid tumor, regardless of its particular strain and unique genetic makeup, providing a more universal approach to cancer. The cell bank would potentially be able to supply a range of cell therapies to deal with different types of solid tumors, and it uses a cell therapy system known as Neutrophil only Leukocyte Infusion Therapy (N-LIfT). The system uses an ex-vivo approach and could be more cost-effective than other approaches using leukocyte therapy.

The company is initially going after a form of pancreatic cancer known as pancreatic ductal adenocarcinoma (PDAC), which has a very low survival rate, with only 3% of patients diagnosed surviving for five years. The company is currently finishing up preclinical research prior to launching a human clinical trial. The goal of the trial will be to demonstrate remission in high unmet need solid tumour cancers by 2021, which will include pancreatic cancers such as PDAC.

Link: https://www.leafscience.org/kizoo-announces-support-for-n-lift-cancer-immunotherapy/

Comments

Awesome!

Posted by: Thomas at August 15th, 2019 11:13 AM

When any firm / lab / researcher uses a phrase like "universal cancer therapy", in the pre-clinical stage, run in the opposite direction

It shows they either have little to no understanding of the disease(s) that make up cancer and their respective heterogeneity, or they are a scam

Posted by: Jason Zeblinsky at August 15th, 2019 12:19 PM

"When any firm / lab / researcher uses a phrase like "universal cancer therapy", in the pre-clinical stage, run in the opposite direction

It shows they either have little to no understanding of the disease(s) that make up cancer and their respective heterogeneity, or they are a scam"

As far as I can tell that's not what's being claimed except (sort of) by Reason, and I have to say that's rather irresponsible wording on his part. What they actually seem to be doing i looking at an cell based immunotherapy for pancreatic cancer specifically, and hope in the future to generalize this approach to more types of solid cancer; saying "a more universal cancer therapy" is just marketing speak for "and if this works we'll see if we can change it up a bit for other cancers to get a whole new drug with minimal effort."

Posted by: Dylan Mah at August 15th, 2019 3:55 PM

"When any firm / lab / researcher uses a phrase like "universal cancer therapy", in the pre-clinical stage, run in the opposite direction

It shows they either have little to no understanding of the disease(s) that make up cancer and their respective heterogeneity, or they are a scam"

Well okay, Reason and LEAF seem to both be editorializing this, I'll check what the company is claiming later on.

Posted by: Dylan Mah at August 15th, 2019 3:58 PM

Wow, didn't know that LEF had to step in to save this line of research.

Posted by: jimofoz at August 15th, 2019 7:45 PM

@jimofoz
In fact, it wasn't LEAF who stepped in, but Kizoo. But I'm glad they're not the only ones.

Posted by: Nicolai at August 17th, 2019 11:40 AM

@Nicolai - LEF stands for "Life Extension Foundation" who are a different group to LEAF, the "Life Extension Advocacy Foundation". This is very confusing, even to close followers of the longevity field such as yourself, which is why it is good that LEAF will be adopting the branding of its crowdfunding site lifespan.io soon.

LEF gave $800,000 to this approach to cancer therapy back in 2010 when it became clear it wasn't going to get any regular funding:

https://www.fightaging.org/archives/2010/07/lef-funds-granulocyte-cancer-therapy/

Posted by: jimofoz at August 21st, 2019 4:11 AM

Post a comment; thoughtful, considered opinions are valued. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.